Arrevus, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Arrevus, Inc. - overview
Established
2015
Location
Durham, NC, US
Primary Industry
Biotechnology
About
Arrevus, Inc. is a biopharmaceutical company focused on developing innovative therapies for rare and orphan diseases. Their research is at the forefront of advancing treatment options for patients in need. Founded in 2015 and headquartered in Durham, US, Arrevus, Inc.
specializes in the development of small molecule treatments. The company was acquired by Aceragen, Inc. in November 2021. The acquisition supports the advancement of clinical studies for their lead compounds, ACG-801 and ACG-721, aimed at addressing rare disease indications.
The company was co-founded by industry professionals dedicated to innovation in healthcare. Arrevus, Inc. focuses on developing oral, small molecule treatments specifically targeting rare and orphan diseases. Their pipeline includes ACG-801 and ACG-721, both in late-stage development, which are designed to improve patient outcomes in challenging therapeutic areas.
As of the latest available information, Arrevus, Inc. does not publicly disclose specific revenue figures. However, the company’s financial activity includes revenue generated through strategic partnerships and clinical development agreements, aimed at facilitating the advancement of its therapeutic pipeline. Following its acquisition in November 2021, Arrevus, Inc.
plans to launch clinical studies for ACG-801 and ACG-721, both targeting rare and orphan diseases. The company aims to leverage the resources from this acquisition to enhance its research capabilities and expand its footprint in the biopharmaceutical industry, focusing on new therapeutic areas by late 2023.
Current Investors
Aceragen, Inc.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.arrevus.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Arrevus, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Arrevus, Inc. | - |
Displaying 1 - 1 of 1
Arrevus, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.